Trials / Completed
CompletedNCT03090113
Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
A Random, Double-blind, Parallel, Placebo-controlled, Multi-center Study of Shuxuetong for Prevention of Recurrence in Acute Cerebrovascular Events With Embolism
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 2,416 (actual)
- Sponsor
- Beijing Tiantan Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This is a randomized, double blind, placebo-controlled, parallel, multicenter research in order to evaluate the effect of Shuxuetong injection in prevention of symptomatic or asymptomatic new cerebral infarction within 10 days. Subgroup study：Evaluate the role of advanced diagnostic technique in identifying potential causes of Embolic Stroke of Undetermined Source (ESUS).
Detailed description
Shuxuetong injection or Placebo injection for 10days. About 2416 patients randomized at 80 centers all over China with 20 subgroup study centers. Face to face interview at baseline, 10 days, and 90 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Shuxuetong Injection | intravenous drip |
| DRUG | Placebo Injection | intravenous drip |
Timeline
- Start date
- 2017-05-12
- Primary completion
- 2019-03-30
- Completion
- 2019-06-21
- First posted
- 2017-03-24
- Last updated
- 2020-07-22
Locations
48 sites across 1 country: China
Source: ClinicalTrials.gov record NCT03090113. Inclusion in this directory is not an endorsement.